

### New Brand Drug Pipeline

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Baclofen Granules (Lyvispah <sup>™</sup> )	Muscle Relaxant	Muscle Spasms	Launch pending. Approved November 22, 2021.
Celecoxib/Tramadol (Seglentis <sup>®</sup> )	NSAID/Opioid Agonist	Pain	Launch anticipated in 2022. Approved October 19, 2021.
Naloxone Injection (Zimhi <sup>™</sup> )	Opioid Antagonist	Opioid Overdose	Launch anticipated in 2022. Approved October 18, 2021.
Celecoxib Oral Liquid (Elyxyb <sup>™</sup> )	NSAID	Migraine Headache Treatment	Launch pending. Approved May 5, 2020.
Buprenorphine Depot Injection (Brixadi <sup>™</sup> )	Opioid Agonist	Treatment of Opioid Addiction	FDA review pending.
Oxycodone (Aximris XR <sup>™</sup> )	Opioid Analgesic – Extended Release	Pain	FDA review pending.
Ansofaxine	Antidepressant	Major Depressive Disorder	FDA review pending.
Nalmefene Injection	Opioid Antagonist	Opioid Overdose	FDA review pending.

### Generic Pipeline

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Dabigatran (Pradaxa <sup>®</sup> )	Anticoagulant	Treatment/ Prophylaxis of Deep Vein Thrombosis	First patent set to expire December 2021. Generic anticipated June 2022.
Oxycodone HCl (Oxaydo <sup>®</sup> )	Opioid Agonist	Pain	Generic exclusivity anticipated in 2022.
Apixaban (Eliquis <sup>®</sup> )	Anticoagulant	Treatment/ Prophylaxis of Deep Vein Thrombosis	Generics approved December 23, 2019, but settlements expected to delay launch for at least a few years.
Diclofenac Potassium (Zipsor <sup>®</sup> ) Capsule	NSAID	Pain	Patent set to expire March 2022.

### Available in the Last 12 Months

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Naloxone Nasal Spray (Kloxxado™)	Opioid Antagonist	Opioid Overdose	August 2021

### Newly Available Generics

Naloxone HCl (Narcan®) Nasal Spray	Opioid Antagonist	Opioid Overdose	December 2021
Zolmitriptan Nasal Spray (Zomig®)	Serotonin Agonist	Migraine Headache Treatment	November 2021
Nebivolol (Bystolic®)	Beta Blocker	High Blood Pressure	September 2021
Ibuprofen/Famotidine (Duexis®)	NSAID/H-2 Receptor Antagonist	Pain/Inflammation	August 2021
Pregabalin Extended Release (Lyrica® CR)	Anticonvulsant	Neuropathic Pain	April 2021
Hydrocodone Bitartrate (Hysingla™ ER)	Opioid Agonist – Extended Release	Pain	March 2021
Topiramate ER Capsule (Qudexy® XR)	Anticonvulsant	Headache, Neuropathic Pain	February 2021

### Discontinuations & Withdrawals

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Naloxone HCl (Evzio®)	Opioid Antagonist	Opioid Overdose	The manufacturer made a business decision to discontinue in September 2020.